Labcorp Holdings annual ebitda margin
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings EBITDA Margin Growth & History (LH)
Labcorp Holdings's ebitda margin was 14.81% for fiscal 2025.
View full Labcorp Holdings company overviewLabcorp Holdings annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 14.81% | +1.51 pp |
| 2024 | 2024-12-31 | 13.30% | +2.59 pp |
| 2023 | 2023-12-31 | 10.71% | −5.92 pp |
| 2022 | 2022-12-31 | 16.64% | −10.96 pp |
| 2021 | 2021-12-31 | 27.60% | +5.64 pp |
| 2020 | 2020-12-31 | 21.96% | +5.46 pp |
| 2019 | 2019-12-31 | 16.51% | −0.06 pp |
| 2018 | 2018-12-31 | 16.57% | −1.27 pp |
| 2017 | 2017-12-31 | 17.83% | −0.69 pp |
| 2016 | 2016-12-31 | 18.53% | +1.77 pp |
| 2015 | 2015-12-31 | 16.76% | −2.47 pp |
| 2014 | 2014-12-31 | 19.23% | −1.79 pp |
| 2013 | 2013-12-31 | 21.02% | −1.08 pp |
| 2012 | 2012-12-31 | 22.10% | +0.81 pp |
| 2011 | 2011-12-31 | 21.29% | −2.34 pp |
| 2010 | 2010-12-31 | 23.63% | −0.46 pp |
| 2009 | 2009-12-31 | 24.09% | +1.39 pp |
| 2008 | 2008-12-31 | 22.70% | −0.40 pp |
| 2007 | 2007-12-31 | 23.10% | — |
Labcorp Holdings quarterly ebitda margin
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.90% | +0.89 pp |
| Q1 2026 | 2026-03-31 | 15.66% | +0.93 pp |
| Q4 2025 | 2025-12-31 | 12.53% | +0.91 pp |
| Q3 2025 | 2025-09-30 | 15.93% | +3.27 pp |
| Q2 2025 | 2025-06-30 | 16.01% | +1.99 pp |
| Q1 2025 | 2025-03-31 | 14.73% | −0.25 pp |
| Q4 2024 | 2024-12-31 | 11.63% | +10.85 pp |
| Q3 2024 | 2024-09-30 | 12.66% | −0.36 pp |
| Q2 2024 | 2024-06-30 | 14.02% | +0.54 pp |
| Q1 2024 | 2024-03-31 | 14.98% | −0.56 pp |
| Q4 2023 | 2023-12-31 | 0.78% | −2.73 pp |
| Q3 2023 | 2023-09-30 | 13.03% | −4.70 pp |
| Q2 2023 | 2023-06-30 | 13.49% | −4.99 pp |
| Q1 2023 | 2023-03-31 | 15.53% | −6.25 pp |
| Q4 2022 | 2022-12-31 | 3.50% | −46.86 pp |
| Q3 2022 | 2022-09-30 | 17.72% | −5.73 pp |
| Q2 2022 | 2022-06-30 | 18.47% | −4.73 pp |
| Q1 2022 | 2022-03-31 | 21.78% | −8.06 pp |
| Q4 2021 | 2021-12-31 | 50.37% | +17.47 pp |
| Q3 2021 | 2021-09-30 | 23.46% | −7.33 pp |
| Q2 2021 | 2021-06-30 | 23.20% | +7.25 pp |
| Q1 2021 | 2021-03-31 | 29.84% | +31.54 pp |
| Q4 2020 | 2020-12-31 | 32.90% | +16.23 pp |
| Q3 2020 | 2020-09-30 | 30.78% | +14.25 pp |
| Q2 2020 | 2020-06-30 | 15.95% | −0.61 pp |
| Q1 2020 | 2020-03-31 | −1.70% | −17.95 pp |
| Q4 2019 | 2019-12-31 | 16.67% | +0.69 pp |
| Q3 2019 | 2019-09-30 | 16.53% | −0.30 pp |
| Q2 2019 | 2019-06-30 | 16.56% | −1.15 pp |
| Q1 2019 | 2019-03-31 | 16.25% | +0.52 pp |
| Q4 2018 | 2018-12-31 | 15.98% | −1.35 pp |
| Q3 2018 | 2018-09-30 | 16.83% | −0.71 pp |
| Q2 2018 | 2018-06-30 | 17.71% | −0.36 pp |
| Q1 2018 | 2018-03-31 | 15.74% | −2.75 pp |
| Q4 2017 | 2017-12-31 | 17.33% | +0.07 pp |
| Q3 2017 | 2017-09-30 | 17.54% | −0.89 pp |
| Q2 2017 | 2017-06-30 | 18.07% | −2.13 pp |
| Q1 2017 | 2017-03-31 | 18.49% | +14.11 pp |
| Q4 2016 | 2016-12-31 | 17.25% | +1.60 pp |
| Q3 2016 | 2016-09-30 | 18.43% | −0.02 pp |
| Q2 2016 | 2016-06-30 | 20.20% | +0.78 pp |
| Q1 2016 | 2016-03-31 | 4.38% | −8.73 pp |
| Q4 2015 | 2015-12-31 | 15.65% | — |
| Q3 2015 | 2015-09-30 | 18.46% | −0.87 pp |
| Q2 2015 | 2015-06-30 | 19.42% | — |
| Q1 2015 | 2015-03-31 | 13.11% | −6.02 pp |
| Q3 2014 | 2014-09-30 | 19.33% | −1.36 pp |
| Q1 2014 | 2014-03-31 | 19.13% | −2.91 pp |
| Q4 2013 | 2013-12-31 | 19.12% | −0.42 pp |
| Q3 2013 | 2013-09-30 | 20.69% | −0.64 pp |
| Q2 2013 | 2013-06-30 | 22.22% | −1.11 pp |
| Q1 2013 | 2013-03-31 | 22.03% | −2.12 pp |
| Q4 2012 | 2012-12-31 | 19.55% | −2.80 pp |
| Q3 2012 | 2012-09-30 | 21.33% | +0.17 pp |
| Q2 2012 | 2012-06-30 | 23.33% | +3.13 pp |
| Q1 2012 | 2012-03-31 | 24.16% | +2.68 pp |
| Q4 2011 | 2011-12-31 | 22.35% | −0.17 pp |
| Q3 2011 | 2011-09-30 | 21.15% | −1.24 pp |
| Q2 2011 | 2011-06-30 | 20.20% | −5.69 pp |
| Q1 2011 | 2011-03-31 | 21.48% | −2.33 pp |
| Q4 2010 | 2010-12-31 | 22.52% | −0.28 pp |
| Q3 2010 | 2010-09-30 | 22.40% | −1.60 pp |
| Q2 2010 | 2010-06-30 | 25.89% | +1.22 pp |
| Q1 2010 | 2010-03-31 | 23.81% | −1.09 pp |
| Q4 2009 | 2009-12-31 | 22.80% | — |
| Q3 2009 | 2009-09-30 | 24.00% | +2.20 pp |
| Q2 2009 | 2009-06-30 | 24.66% | — |
| Q1 2009 | 2009-03-31 | 24.90% | — |
| Q3 2008 | 2008-09-30 | 21.80% | — |
Labcorp Holdings ebitda margin trends
Over the last five fiscal years, Labcorp Holdings's ebitda margin decreased from 21.96% to 14.81%, a change of −7.16 percentage points. The latest reported quarter, Q2 2026, shows 16.90%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...